{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T05:11:10Z","timestamp":1650431470181},"reference-count":14,"publisher":"Japanese Society of Internal Medicine","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Jpn. Soc. Intern. Med.","J. Jpn. Soc. Intern. Med"],"published-print":{"date-parts":[[2013]]},"DOI":"10.2169\/naika.102.2631","type":"journal-article","created":{"date-parts":[[2014,10,9]],"date-time":"2014-10-09T23:26:53Z","timestamp":1412897213000},"page":"2631-2638","source":"Crossref","is-referenced-by-count":0,"title":["3. Opportunistic Infections"],"prefix":"10.2169","volume":"102","author":[{"given":"Keiichi","family":"Sumida","sequence":"first","affiliation":[{"name":"Nephrology Center and Department of Rheumatology, Toranomon Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshifumi","family":"Ubara","sequence":"additional","affiliation":[{"name":"Nephrology Center and Department of Rheumatology, Toranomon Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Falagas ME, et al: Infection-related morbidity and mortality in patients with connective tissue diseases: a systematic review. Clin Rheumatol 26: 663-670, 2007.","DOI":"10.1007\/s10067-006-0441-9"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Doran MF, et al: Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 46: 2287-2293, 2002.","DOI":"10.1002\/art.10524"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Doran MF, et al: Predictors of infection in rheumatoid arthritis. Arthritis Rheum 46: 2294-2300, 2002.","DOI":"10.1002\/art.10529"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Strangfeld A, et al: Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis 70: 1914-1920, 2011.","DOI":"10.1136\/ard.2011.151043"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Greenberg JD, et al: Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA Registry. Ann Rheum Dis 69: 380-386, 2010.","DOI":"10.1136\/ard.2008.089276"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Schneeweiss S, et al: Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum 56: 1754-1764, 2007.","DOI":"10.1002\/art.22600"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Curtis JR, et al: Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum 56: 1125-1133, 2007.","DOI":"10.1002\/art.22504"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Franklin J, et al: Risk and predictors of infection leading to hospitalization in a large primary-care-derived cohort of patients with inflammatory polyarthritis. Ann Rheum Dis 66: 308-312, 2007.","DOI":"10.1136\/ard.2006.057265"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Komano Y, et al: Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety. J Rheumatol 38: 1258-1264, 2011.","DOI":"10.3899\/jrheum.101009"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Schiff M, et al: Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 67: 1096-1103, 2008.","DOI":"10.1136\/ard.2007.080002"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Koike T, et al: Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients. Ann Rheum Dis 70: 2148-2151, 2011.","DOI":"10.1136\/ard.2011.151092"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Komano Y, et al: <i>Pneumocystis jiroveci<\/i> pneumonia in patients with rheumatoid arthritis treated with infliximab: a retrospective review and case-control study of 21 patients. Arthritis Rheum 61: 305-312, 2009.","DOI":"10.1002\/art.24283"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Tanaka M, et al: <i>Pneumocystis jirovecii<\/i> pneumonia associated with etanercept treatment in patients with rheumatoid arthritis: a retrospective review of 15 cases and analysis of risk factors. Mod Rheumatol 22: 849-858, 2012.","DOI":"10.1007\/s10165-012-0615-z"}],"container-title":["Nihon Naika Gakkai Zasshi"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/naika\/102\/10\/102_2631\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T18:44:07Z","timestamp":1650393847000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/naika\/102\/10\/102_2631\/_article\/-char\/ja\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013]]},"references-count":14,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.2169\/naika.102.2631","relation":{},"ISSN":["0021-5384","1883-2083"],"issn-type":[{"value":"0021-5384","type":"print"},{"value":"1883-2083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013]]}}}